Sign up for you and your loved ones to receive the latest news and updates about CAR T-Cell Immunotherapy.
Copyright © 2021 Malaysian Genomics Resource Centre Berhad (652790-V). All Rights Reserved.
Immunotherapy is now hailed as the fifth pillar of cancer treatments. Especially beneficial for late-stage patients, immunotherapy utilises and enhances a patient’s own immune system’s ability to identify, target, restrict and eliminate cancer – resulting in better survival rate, improved life expectancy, fewer side effects and increased quality of life for the patient.
MGRC is a public listed company founded in 2004. We are focused on realising the enormous potential within the evolving space of health technologies. Being a genomics and biopharmaceutical company, we are committed to provide the latest immunotherapies in Asia with our new state-of-the-art laboratory – offering new hope in the battle against cancer.